| Summary: | Our previous studies demonstrate that ammonia induces doxorubicin release from Doxil® in a concentration-dependent manner. Because ammonia that results from glutaminolysis is continu-ously generated in tumors at high enough concentration to induce doxorubicin release of Doxil in tumors, this may explain why doxorubicin release in interstitial tumor fluids is much faster and higher than in the plasma, in which release is minimal. This unique activity of tumor ammo-nia may explain, at least in part, the therapeutic efficacy of Doxil, which in practice does not re-lease doxorubicin in animal and human plasma. Our current study aims to evaluate if tumor-specific metabolites other than ammonia (such as lactate and pyruvate) are also involved in doxorubicin release from Doxil. Also, we studied levels of ammonia in other mouse organs. Our data shows that these other metabolites do not affect doxorubicin release. Furthermore, using the Metabolic gEne RApid Visualizer database (MERAV), we computationally explored the relation-ships of glutaminase (GLS) 1 and 2, glutamate dehydrogenase (GLUD)1 and 2, as well as gluta-mine transporters the glutaminolysis levels found in different cancers. This result could not be achieved without the upregulation of glutamine transporters. Indeed, our queries to MERAV showed that SLC38A1, SLC38A2, and especially SLC38A6, are upregulated in cancerous tis-sues. We discuss how the information on the upregulation of enzymes related to glutaminolysis could be used for “precision medicine” to determine if Doxil is an appropriate choice for a spe-cific cancer patient. Our computational exploration shows that glutaminolysis is heightened in some cancerous tissues as instead of their normal counterparts, but not in all cases. It would be possible and perhaps advantageous to test individual patient tissues to determine glutaminolysis, and therefore likely, ammonium levels in cancerous tissues, and to use this to ascertain if Doxil would be a good treatment choice.
|
|---|
